摘要
Funding for the development of this Practice Guideline and Guidance was provided by the American Association for the Study of Liver Diseases. Potential conflict of interest: Dr. Mack consults for Albireo. Dr. Kerkar advises High Tide and received royalties from Elsevier. Dr. Manns consults for, is on the speakers’ bureau for, and received grants from Falk. He consults for and received grants from Novartis. Dr. Vierling advises and received grants from CymaBay, Enanta, Genkyotex, Intercept, Lilly, Novartis, and TaiwanJ. He advises Arena, BioIncept, Blade, and GlaxoSmithKline and received grants from Allergan and NGM. What’s New Since 2010 Guidelines? Histological features of NAFLD are present in 17%‐30% of adult patients with AIH, and concurrent NAFLD may influence response to therapy. Diagnostic scoring systems should be used only to support clinical judgment in challenging cases of AIH and to define AIH cohorts for clinical studies. Immune checkpoint inhibitors have been associated with immune‐mediated liver injury and are frequently steroid‐responsive, but the liver injury lacks autoantibodies and typical histological features of AIH. Elastography may be used to assess the stages of hepatic fibrosis noninvasively. Testing for TPMT activity prior to AZA treatment is encouraged in all patients. Budesonide and AZA or predniso(lo)ne and AZA are recommended as first‐line AIH treatments in children and adults who do not have cirrhosis, acute severe hepatitis, or ALF. AZA can be continued throughout pregnancy, whereas the use of MMF is contraindicated in pregnancy. Liver tissue examination prior to drug withdrawal in individuals with ≥2 years of biochemical remission is preferred but not mandatory in adults and required in children. MMF or TAC can be used as second‐line treatment in children and adults with AIH who have failed to respond to first‐line therapy. Patients with acute severe AIH should receive predniso(lo)ne followed by LT if no improvement within 2 weeks, whereas patients with AIH and ALF should be evaluated directly for LT. Glucocorticoids can be discontinued after LT and patients monitored for recurrence of AIH. Purpose and Scope The objectives of this document are to provide guidance in the diagnosis and management of autoimmune hepatitis (AIH) based on current evidence and expert opinion and to present guidelines to clinically relevant questions based on systematic reviews of the literature and the quality of evidence.1 This practice guideline/guidance constitutes an update of the guidelines on AIH published in 2010 by the American Association for the Study of Liver Diseases (AASLD).2 It updates the epidemiology, diagnosis, management, and outcomes of AIH in adults and children. The document is divided into “guideline recommendations” and “guidance statements.” Guideline recommendations were based on evidence derived from systematic reviews of the medical literature and supported, if appropriate, by meta‐analyses. The systematic reviews and meta‐analyses were conducted independently by the Mayo Clinic Evidence‐Based Practice Center. Findings were analyzed and interpreted by a multidisciplinary panel of experts, including both content and methodology experts, who rated the quality of evidence and determined the strength of each recommendation. The quality of clinical evidence was determined by its source (e.g., randomized controlled trial or observational study), and the strength of the recommendation was determined by assessing the quality of evidence, balance of benefits and harms, patient values and preferences, and use of resources and costs. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to categorize each recommendation as strong or conditional (Table 1).3 Details of the methodology, systematic reviews, and meta‐analyses are published separately. The guideline recommendations focus on pertinent management issues for which sufficient evidence was available to render a recommendation. They address glucocorticoid and azathioprine therapy as first‐line management, second‐line medications after failure of first‐line therapy, and maintenance management after liver transplantation (LT; see Supporting Table S1 for patient/intervention/comparison/outcome questions related to systematic reviews). Table 1 - GRADE Assessment of Clinical Studies Study Design Rating Quality Strength Determinants Strength and Implications of Recommendation Randomized controlled trial High Quality of evidence Strong Moderate Balance of benefits and harms Most people would want course Most people should take course Can be adapted as policy in most cases Low Patient values and preferences Observational Very low Resources and costs Conditional Feasibility Many people would select course Requires decision aids and shared decision‐making Debatable policy choice Acessibility Equity Quality downgrades: selection bias, inconsistency, imprecision, indirectness, publication bias. Quality upgrades: large effect, very large effect, dose–response gradient, confounders produce no effect. “Guidance statements” were developed by consensus of an expert panel based on formal review and analysis of the published literature on the topic. The quality (level) of evidence and the strength of each guidance statement were not formally rated for the guidance statements. “Guidance statements” were used to address topics for which a sufficient number of randomized controlled trials were not available to justify a systematic review and meta‐analysis. The “guidance statements” and “guideline recommendations” were also reviewed by members of the AIH Association, a 501(c)(3) nonprofit organization, in order to incorporate patient and public perspectives. “Guidance statements” and “guideline recommendations” are intended to provide health care practitioners with updated information and rigorously assessed, evidence‐based recommendations. They are intended to aid, not supersede, clinical judgment. For ease of reading this AIH guidance/guidelines document, a glossary of definitions is provided in Table 2. Table 2 - Definitions of AIH and Its Treatment Outcomes Condition Definition AIH Characteristic histologic abnormalities (lymphoplasmacytic interface hepatitis), elevated AST, ALT, and total IgG and the presence of one or more characteristic autoantibodies Inactive cirrhosis Absence of inflammatory infiltrates in both portal tracts and fibrous bands in cirrhosis Acute severe AIH Jaundice, INR > 1.5 < 2, no encephalopathy; no previously recognized liver disease370 ALF INR ≥ 2; hepatic encephalopathy within 26 weeks of onset of illness; no previously recognized liver disease100 Biochemical remission Normalization of AST, ALT, and Histological remission Absence of in liver tissue after treatment Treatment failure or histological with therapy response of and histological are to for remission of activity after of remission and drug withdrawal Treatment to maintenance therapy to with cirrhosis in biochemical remission may have of AIH is an immune‐mediated inflammatory liver of which all both and all Patients may be be or present with acute liver failure and the diagnosis be in all patients with acute or liver including patients with after LT. AIH not have a and the diagnosis the presence of a of typical features which can patients with the and can in liver to hepatic cirrhosis, from liver or LT are Treatment with been but management may be associated with and AIH all and within all and its to by and have a of AIH more present with cirrhosis, and have of and a of recurrence after LT to in adults and children the onset of AIH and but the may have been by onset have been in and New The of AIH on the and the in adults from to 2 cases of New are from to the been a in in and the The of AIH in adults from to The in children from and to with autoimmune the in AIH within the which the by most and from within and associated with AIH are the of AIH also but the for of AIH are for for AIH been associated with of or and of and the of or of may the and of and and inflammatory and AIH is a and is AIH associated with an in the autoimmune on which been associated with autoimmune 1 in the and as or can as for of to in to and to hepatic as the of and of and to in the of produce are by and to on and of to of of the of AIH. a of the of AIH, in which a in to hepatic and the are of to hepatic hepatic or to as or the present to on and and by to is a which of required for and of (e.g., and both and the of by of a of including of of into of development and and The is the failure of and and to hepatic of to can from into The is the of portal inflammatory infiltrates of of and of in of which and and portal in cirrhosis in the of therapy. of the to into and in the presence of of and of by by to and tissue can the and of all and of may a in of into also of AIH. Low of and of of with by in the in can of and and may into infiltrates of and including and and can within the portal and of into of into and hepatitis of and in patients with AIH. and of of and by of and autoantibodies may of Diagnostic and The diagnosis of AIH is based on histological abnormalities hepatitis), characteristic clinical and and and IgG and the presence of one or more characteristic AIH lacks a and the diagnosis characteristic features and the of may (e.g., hepatitis, liver are of AIH, based on the autoantibodies are 1 is by and 2 is by to liver 1 in the of and The characteristic clinical features of are in Table to of AIH cases are for and the presence of characteristic features of AIH AIH is autoantibodies may be as in Table and 2. of AIH into in management and aids in outcomes in but may be in Table - Characteristic of 1 and 2 AIH 1 AIH 2 AIH and adults of Acute onset or Acute liver failure in Acute in Acute severe in features may be with in in children with in adults after drug withdrawal Table - in the of AIH Diagnostic 1 1 2 1 after with 1 1 1 2 2 of 1 autoimmune Diagnostic for the of AIH after of and and should be in adults and to should be if and are and should be in all patients The of the liver support the diagnosis of AIH or an AIH with or The of and can to tissue and for one of autoantibodies support the diagnosis of AIH or including tissue and the for the diagnosis of AIH (Table are in of American adults with AIH are present in and are present in of patients with AIH have or as an and have can also as an in hepatitis hepatitis liver and liver and can as an in hepatitis and liver and are concurrent in of liver of AIH, and the for AIH from to if autoantibodies are are in the of and and this after for and have a low for AIH in American adults and after the of and is in patients. are in of and children with and of and are in adults and children and treatment but are not of activity or treatment to liver are present in of patients with 1 AIH, and have for the (Table have been the of AIH in of and have been associated with severe and after drug are frequently present in patients with 1 AIH but in and liver may be the only autoantibodies are a of and are present in of patients with AIH and (Table to is an is present in of patients with AIH and of patients with to and been associated with severe acute AIH, treatment and to liver 1 are present in of patients with and in children with severe liver (Table are present in of patients with 2 and may be in and have not been rigorously in the should be and with the clinical may be on of the and in with the Histological Findings The diagnosis of AIH be liver and histological hepatitis is the histological of AIH, by in and hepatitis in is also in and with in patients with and is the of one into with both to is present in of patients with AIH, and are present in of the histological is for AIH, but the of interface hepatitis with portal or into the and are typical of Histological features characteristic of AIH. inflammatory of the portal and interface hepatitis of the portal and in a portal inflammatory and of a and and of and are of of of is present in of adults in the as as in of in of adults with or The histological examination is to or concurrent the of inflammatory and the of may be present in patients with but the clinical of this Histological of are present in 17%‐30% of patients with and liver tissue examination may patients with AIH and who are of and The histological features of AIH with ALF in the and of is present in inflammatory in hepatic in and in of patients with ALF have or all of Diagnostic The scoring system of the was by an panel in in and in Table The scoring system for AIH to the scoring system whereas the scoring system and clinical judgment as the The scoring system is for patients with or whereas the scoring system is most for typical of patients with the scoring system should be the system a low a of to the of the a of and a of were associated with AIH. The scoring system can be to children and in adults as of the for the in the with the or may the of the scoring system for children by the of to the and scoring systems of by of in the of concurrent or liver failure to as and on by by Diagnostic scoring systems can in a diagnosis of AIH in challenging but are most in cohorts of patients with AIH for clinical Guidance The diagnosis of AIH histological and is by the elevated elevated IgG of and may AIH. should of and in adults and and in if to the challenging cases should be reviewed by or to an liver prior to therapy. Clinical Most patients with AIH present after the development of or is the in of and may be of or is with the and a are from of liver or of autoimmune inflammatory AIH is in of patients improvement may have histological to of frequently within and a is of patients with more severe The of should not Acute and ALF AIH with an acute onset in of ALF associated with hepatic encephalopathy in of American and definitions in Table or a or liver injury on previously AIH liver be are or in of patients with acute severe AIH, and the IgG is in Histological is a hepatitis, and interface hepatitis support the diagnosis of acute and features in the presence of cirrhosis and hepatic can be in AIH with within the liver in of patients with acute severe AIH and may be and are in of American and patients as hepatitis and as AIH by the scoring of AIH have been in and by including clinical judgment and glucocorticoid and may be in the course of the or the of and may the diagnosis to Guidance The diagnosis of AIH be in all patients with acute or liver including patients with liver and Immune Diseases autoimmune are present in of patients with and have been recognized with in patients with 1 and 2 been the most concurrent autoimmune in 1 AIH whereas 1 autoimmune and autoimmune have been most in 2 is associated with or no but in the of may the liver but in the of the concurrent may the liver of children with AIH may of the of the and autoimmune most frequently in and the by Patients years have autoimmune and more adults years whereas adults more have and autoimmune concurrent autoimmune is more in patients with or a of autoimmune in The of in patients with AIH is in the children with AIH, was present in and features associated with can be with AIH, and concurrent may to the of liver in patients with AIH and who of remission after withdrawal of AIH children Guidance AIH patients should be for and AIH patients should be for autoimmune and autoimmune based on and medical or AIH and or are clinical and not clinical is to individuals who may not respond to treatment for The patients with features of AIH and of the for should be the of or presence of and on histological for AIH in the of to the presence of interface are and IgG or presence of of the and the AIH scoring systems the were more the may not all patients with the who have The the for the diagnosis of have not been independently and is to the and of the They have also the scoring systems for AIH were not developed or for the diagnosis of the and should not be used for this to are present in of patients with AIH in the of histological features of injury or patients respond to glucocorticoid therapy, and do not into Liver tissue examination is required to the and the presence of in patients with AIH is to this for the diagnosis of as autoimmune in the presence of typical features of AIH, of and evidence of by or or evidence of based on fibrosis on is present in of adults with AIH, and of patients with AIH and concurrent have of is present in of children with AIH, and to with Patients with of histological features with or and may have or The diagnosis of should be in all patients with AIH and or to glucocorticoid Guidance Patients with AIH, with and a should be to have Patients with AIH, histological features of injury or and concurrent should be evaluated for by to have the The can in the but the may patients with who have severe the the scoring systems for AIH should be used for assessing liver injury can and an or drug been in of patients with features of and have been most and have been (Table including hepatitis, have been with the use of as the checkpoint The liver associated with the checkpoint inhibitors have with glucocorticoid therapy, but have the and histological features characteristic of cases have been to glucocorticoid therapy and associated with The liver associated with the checkpoint inhibitors should not be with AIH. Table - with Liver AIH Association Association Association from to The clinical of injury is in Table The from drug to onset from weeks to but and can have The clinical should all to and Table - of and AIH Clinical AIH but also Acute onset to with drug or autoimmune in drug Glucocorticoids with after drug withdrawal to cirrhosis transplantation The histological of interface hepatitis with portal and infiltrates of hepatitis, and are to of AIH, for the of fibrosis or cirrhosis in most may be and fibrosis is The diagnosis is by an acute features of published literature on the from drug to liver and of fibrosis or cirrhosis Liver tissue examination is if the diagnosis is severe or the of glucocorticoid therapy is Treatment withdrawal of the with and of clinical and (Table within 1 with and total the of or for LT in of of for the of glucocorticoid to glucocorticoid management are failure of the to after of the or of or the biochemical after glucocorticoid withdrawal the diagnosis of a liver whereas of abnormalities is with should be as AIH with based on the total and a of and of for this is a of The of injury been (Table The have been as or and drug do have a of and for LT in The of the Liver is a for liver It is a of the Liver of the of and and Diseases and the of of the of of Guidance liver injury be in the diagnosis of AIH. The be and to therapy for injury should be or activity are severe (e.g., or if and to or after of the after glucocorticoid withdrawal AIH and the for therapy. Assessment Assessment of by for hepatic the the the and the liver fibrosis have as the in in AIH and in assessing the or of hepatic and of and treatment Assessment of by Liver Elastography or with the histological of fibrosis in but its in fibrosis is within the of liver by is by both and the with histological of of of therapy to hepatic can cirrhosis and stages of fibrosis from severe stages The values fibrosis stages as the of were for ≥ 2, for ≥ and for ≥ in liver with biochemical of and after of Elastography The of with fibrosis and to for hepatic fibrosis in in liver of can have for portal and AIH, the and of for hepatic fibrosis are the fibrosis scoring systems and the ALT, for the diagnosis of cirrhosis in one liver the of fibrosis by the of fibrosis was liver in patients with AIH was in patients This was each fibrosis from to and in in liver by in and patients with AIH have not been but the liver by can be by therapy, by liver or hepatic and have not been in AIH. liver by in and of of are interpreted as in liver The of for cirrhosis and by of have been to in fibrosis ≥2 and by also with the of and may as a to assess of portal can hepatic fibrosis in patients with hepatic severe and hepatic Guidance for hepatic fibrosis are in AIH and should not be can fibrosis or cirrhosis in patients with AIH with but should be for after treatment of AIH in order to the of hepatic Evaluation The of the of patients with AIH are to and an Assessment of of activity patients with or TPMT activity who are for severe with AZA or or TPMT activity in only of the but the of severe may its use an analysis of and for TPMT activity not the of AZA or as and and TPMT activity not the of in Guidance patients with AIH for or TPMT activity prior to treatment with should be reviewed and prior to the of are not recommended in on of whereas and are to are in patients but not low as to Patients with hepatitis and hepatitis should prior to treatment if to and been in most patients with autoimmune liver and the of been and have developed in all patients for and in of patients for with to Guidance should be to all patients with AIH to the guidelines of the for and Patients and should therapy. and of of Patients on are for of and guidelines have been developed of patients for hepatitis and to hepatitis on the and the and of therapy, the of treatment can be as and low on the a treatment or with the of therapy can be therapy, with or treatment and for after treatment after treatment with been recommended for individuals to of with of therapy been recommended for patients low The of in patients with AIH who are with of or in with AZA is the in patients to individuals with who are of by patients but a of patients with AIH who would be for glucocorticoid patients with for but of and in a previously in patients with and have been associated with a low of as glucocorticoid therapy for weeks for autoimmune with the and of and to of for weeks have been associated with a of of Patients with AIH for and to the of and individuals for glucocorticoid therapy can be prior to The of management is to clinical and biochemical remission on glucocorticoid in with and for is in patients. of and of been by the therapy or the of or may the of and is in patients. the of therapy in patients should be Guidance Patients with AIH who are the of should therapy with or in with AZA to and the for therapy. Patients with evidence of who are with or are for and should be for therapy. by of and should be in patients with for and years in adult patients with for The most are or use of of and years for and years for and been recommended for patients on glucocorticoid in of patients with and severe in justify of the in all patients diagnosis and as and are used in children. Clinical trials support the use of is can and as a for The is by a of for and 2 may be or by glucocorticoid therapy, and its presence should be prior to the of therapy. The of the are low and or of the justify the The presence of or treatment of the glucocorticoid and and Guidance should be in all adult patients with AIH who have for and should be years of glucocorticoid of should be determined diagnosis and with and should be provided on glucocorticoid therapy and as clinically in patients with therapy is for patients with AIH and Assessment for all features of should be prior to and therapy, and its presence may treatment and should be prior to treatment to patients not only the of the but also the benefits of remission and the associated with or are patients with and are more in patients with AIH in the of is in and severe in of and with to the and of the and its and can to Low on quality of have been associated with glucocorticoid may be glucocorticoid The of and may on treatment of and in the quality of should be monitored throughout management of AIH as may justify in the of or or can be by as the the of the Patient and the Guidance Potential to should be and the of treatment and monitored of and in the quality of should be monitored throughout management of AIH, and can be by The of AIH and its medications on health should be if on and outcomes of in AIH are derived from and AIH is whereas are not but in with AIH The is in with The and of is for the but to for with are associated with and may be a but of in of but are no associated with AIH. The the or within of is is to a in AIH. in patients who are not on therapy or who have not been in remission the prior to Patients with AIH who are or within the should be continued on treatment to the of and hepatic are more and the low of may in to the of patients with cirrhosis, in can to an of and of with is as and have in (Table The of been in Table - of in the Patient with AIH in but with abnormalities AZA MMF TAC in Glucocorticoids from an of and the